US 12,109,225 B2
Methods for potentiating cancer treatment using ionizing radiation
Won Yong Lee, Bountiful, UT (US); Thomas P. Kennedy, Williamsburg, VA (US); and Glenn D. Prestwich, Spokane, WA (US)
Assigned to GLYCOMIRA THERAPEUTICS, INC., Salt Lake City, UT (US)
Appl. No. 17/293,103
Filed by GLYCOMIRA THERAPEUTICS, INC., Salt Lake City, UT (US)
PCT Filed Nov. 11, 2019, PCT No. PCT/US2019/060834
§ 371(c)(1), (2) Date May 12, 2021,
PCT Pub. No. WO2020/102137, PCT Pub. Date May 22, 2020.
Claims priority of provisional application 62/760,134, filed on Nov. 13, 2018.
Prior Publication US 2021/0401873 A1, Dec. 30, 2021
Int. Cl. A61K 38/00 (2006.01); A61K 31/737 (2006.01); A61K 41/00 (2020.01); A61N 5/10 (2006.01)
CPC A61K 31/737 (2013.01) [A61K 41/0038 (2013.01); A61N 5/1001 (2013.01); A61N 5/1077 (2013.01); A61N 5/1084 (2013.01); A61N 2005/1024 (2013.01); A61N 2005/1087 (2013.01); A61N 2005/109 (2013.01); A61N 2005/1091 (2013.01); A61N 2005/1098 (2013.01)] 12 Claims
 
1. A method for reducing or maintaining the size of a tumor in a subject, the method comprising exposing the tumor to ionizing radiation and administering subcutaneously or intravenously to the subject a pharmaceutical composition comprising a modified hyaluronan or a pharmaceutically acceptable salt or ester, wherein the modified hyaluronan or its pharmaceutically acceptable salt or ester comprises hyaluronan with at least one primary C-6 hydroxyl position of an N-acetylglucosamine residue substituted with a methyl group, and at least one C-2 hydroxyl proton, at least one hydroxyl proton, or at least one C-3 hydroxyl proton and at least one hydroxyl proton is substituted with a sulfate group, and the modified hyaluronan or its pharmaceutically acceptable salt or ester has an average molecular weight of 2 kDa to 10 kDa.